New Drug Approvals Archive - March 2003

Fuzeon (enfuvirtide)

Date of Approval: March 13, 2003
Company: Roche
Treatment for: HIV Infection

Fuzeon (enfuvirtide) is a fusion inhibitor used in combination with other medicines to treat HIV infection.

• Fuzeon Roche - Treatment for HIV Infection

Femring (estradiol acetate) Vaginal Ring

Date of Approval: March 20, 2003
Company: Galen Ltd
Treatment for: Postmenopausal Symptoms

Femring (estradiol acetate) is a vaginal estrogen product in the form of a flexible, self-inserted ring. Femring is indicated to treat both the hot flushes and vaginal symptoms associated with menopause.

• Femring Galen Ltd - Treatment for Menopausal Vasomotor Symptoms

Somavert (pegvisomant) for Injection

Date of Approval: March 25, 2003
Company: Pharmacia and Upjohn
Treatment for: Acromegaly

Somavert (pegvisomant) is a growth hormone receptor antagonist indicated for the treatment of acromegaly.

• Somavert Pharmacia and Upjohn - Treatment for Acromegaly

Emend (aprepitant) Capsules

Date of Approval: March 27, 2003
Company: Merck
Treatment for: Nausea/Vomiting -- Chemotherapy Induced

Emend (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist used in combination with other antiemetic agents to prevent and control acute and delayed nausea and vomiting associated with chemotherapy.

• Emend Merck - Treatment for Chemotherapy-Induced Nausea and Vomiting (CINV)

Emend (aprepitant)

Patient Population Altered: August 28, 2015

• FDA Approves Pediatric Indication for Emend (aprepitant) Capsules in Combination with Other Antiemetic Agents